Gabriel S. Oliveira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gabriel S. Oliveira has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Cátia Teixeira
LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Porto, Portugal
1 shared publication - Maria Salomé Gomes
I3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
1 shared publication - Paula Gomes
LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre, s/n, 4169-007 Porto, Portugal
1 shared publication - Raquel P. Costa
LAQV-REQUIMTE—Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, P-4050-313 Porto, Portugal
1 shared publication - Tânia Silva
i3S ‐ Instituto de Investigação e Inovação em Saúde Universidade do Porto Porto Portugal
1 shared publication
Latest Publications
- Open Access
- 2 April 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (4) , 323
Antimicrobial Peptides as Potential Anti-Tubercular Leads: A Concise Review
Despite being considered a public health emergency for the last 25 years, tuberculosis (TB) is still one of the deadliest infectious diseases, responsible for over a million deaths every year. The length and toxicity of available treatments and the increasing emergence of multidrug-resistant strains of Mycobacterium tuberculosis renders standard regimens increasingly inefficient and emphasizes the urgency to develop new approaches that are not only cost- and time-effective but also less toxic. Antimicrobial peptides (AMP) are small cationic and amphipathic molecules that play a vital role in the host immune system by acting as a first barrier against invading pathogens. The broad spectrum of properties that peptides possess make them one of the best possible alternatives for a new “post-antibiotic” era. In this context, research into AMP as potential anti-tubercular agents has been driven by the increasing danger revolving around the emergence of extremely-resistant strains, the innate resistance that mycobacteria possess and the low compliance of patients towards the toxic anti-TB treatments. In this review, we will focus on AMP from various sources, such as animal, non-animal and synthetic, with reported inhibitory activity towards Mycobacterium tuberculosis.
- 2 April 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (4) , 323
Open AccessAntimicrobial Peptides as Potential Anti-Tubercular Leads: A Concise Review
Despite being considered a public health emergency for the last 25 years, tuberculosis (TB) is still one of the deadliest infectious diseases, responsible for over a million deaths every year. The length and toxicity of available treatments and the increasing emergence of multidrug-resistant strains of Mycobacterium tuberculosis renders standard regimens increasingly inefficient and emphasizes the urgency to develop new approaches that are not only cost- and time-effective but also less toxic. Antimicrobial peptides (AMP) are small cationic and amphipathic molecules that play a vital role in the host immune system by acting as a first barrier against invading pathogens. The broad spectrum of properties that peptides possess make them one of the best possible alternatives for a new “post-antibiotic” era. In this context, research into AMP as potential anti-tubercular agents has been driven by the increasing danger revolving around the emergence of extremely-resistant strains, the innate resistance that mycobacteria possess and the low compliance of patients towards the toxic anti-TB treatments. In this review, we will focus on AMP from various sources, such as animal, non-animal and synthetic, with reported inhibitory activity towards Mycobacterium tuberculosis.